Keywords: Biogen Idec, Benlysta, Royalty rights, Lupus, GlaxoSmithKline, Human Genome Sciences

Biogen Idec sells Benlysta royalty rights to DRI for initial $18.3 million

Article | 11 September 2012

Print This

US biotech firm Biogen Idec (Nasdaq: BIIB) has sold to a Canada-based DRI Capital managed fund its royalty and other ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in